{"id":399,"date":"2020-07-27T09:50:56","date_gmt":"2020-07-27T09:50:56","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=399"},"modified":"2020-07-27T09:50:56","modified_gmt":"2020-07-27T09:50:56","slug":"26-july-2020-tocilizumab-low-dose-tcz-associated-with-rapid-improvement","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/26-july-2020-tocilizumab-low-dose-tcz-associated-with-rapid-improvement\/","title":{"rendered":"(26 July 2020) Tocilizumab- Low-dose TCZ  associated with rapid improvement"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19<\/p>\n<p>https:\/\/doi.org\/10.1101\/2020.07.20.20157503<\/p>\n<p class=\"\">Results from phase 2 trial (NCT04331795) of low-dose tocilizumab in hospitalized adult patients with Covid-19 are presented.&nbsp; A range of doses from 40 to 200 mg (low-dose tocilizumab) was evaluated, with allowance for one repeat dose at 24-48 hours. The primary objective was to assess the relationship of dose to fever resolution and CRP response. Outcomes were compared with retrospective controls with Covid-19. Correlative studies evaluating host antibody response were performed in parallel.&nbsp; A total of 32 patients received low-dose tocilizumab. This cohort had improved fever resolution (75.0% vs. 34.2%, p = 0.001) and CRP decline (86.2% vs. 14.3%, p &lt; 0.001) in the 24-48 hours following drug administration, as compared to the retrospective controls (N=41). The probabilities of fever resolution or CRP decline did not appear to be dose-related in this small study (p=0.80 and p=0.10, respectively). Within the 28-day follow-up, 5 (15.6%) patients died. For patients who recovered, median time to clinical recovery was 3 days (IQR, 2-5). Clinically presumed and\/or cultured bacterial superinfections were reported in 5 (15.6%) patients. Correlative biological studies demonstrated that tocilizumab-treated patients produced anti-SARS-CoV-2 antibodies comparable to controls. Low-dose tocilizumab was associated with rapid improvement in clinical and laboratory measures of hyperinflammation in hospitalized patients with Covid-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19 https:\/\/doi.org\/10.1101\/2020.07.20.20157503 Results from phase 2 trial (NCT04331795) of low-dose tocilizumab in hospitalized adult patients with Covid-19 are presented.&nbsp; A range of doses from 40 to 200 mg (low-dose tocilizumab) was evaluated, with&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/26-july-2020-tocilizumab-low-dose-tcz-associated-with-rapid-improvement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(26 July 2020) Tocilizumab- Low-dose TCZ  associated with rapid improvement&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/399"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=399"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/399\/revisions"}],"predecessor-version":[{"id":400,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/399\/revisions\/400"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}